no code implementations • 11 Feb 2024 • Zehao Dong, Qihang Zhao, Philip R. O. Payne, Michael A Province, Carlos Cruchaga, Muhan Zhang, Tianyu Zhao, Yixin Chen, Fuhai Li
However, we found two major limitations of existing GNNs in omics data analysis, i. e., limited-prediction (diagnosis) accuracy and limited-reproducible biomarker identification capacity across multiple datasets.
no code implementations • 1 Sep 2023 • Zehao Dong, Muhan Zhang, Philip R. O. Payne, Michael A Province, Carlos Cruchaga, Tianyu Zhao, Fuhai Li, Yixin Chen
We theoretically reveal the trade-off of expressivity and stability in graph-canonization-enhanced GNNs.
no code implementations • 19 Sep 2022 • Zehao Dong, Heming Zhang, Yixin Chen, Philip R. O. Payne, Fuhai Li
Synergistic drug combinations provide huge potentials to enhance therapeutic efficacy and to reduce adverse reactions.
no code implementations • 9 Oct 2021 • Sayantan Kumar, Sean C. Yu, Thomas Kannampallil, Zachary Abrams, Andrew Michelson, Philip R. O. Payne
Complex deep learning models show high prediction tasks in various clinical prediction tasks but their inherent complexity makes it more challenging to explain model predictions for clinicians and healthcare providers.
1 code implementation • 1 Jun 2020 • Fuhai Li, Andrew P. Michelson, Randi Foraker, Ming Zhan, Philip R. O. Payne
Based on the identified signaling pathways and GOs, a set of potentially effective drugs were repurposed by integrating the drug-target and reverse gene expression data resources.
no code implementations • 16 Nov 2018 • Tianyu Zhang, Liwei Zhang, Philip R. O. Payne, Fuhai Li
Drug resistance is still a major challenge in cancer therapy.